142 related articles for article (PubMed ID: 12467306)
1. New insights into the clinical pharmacokinetics of trofosfamide.
Brinker A; Kisro J; Letsch C; Brüggemann SK; Wagner T
Int J Clin Pharmacol Ther; 2002 Aug; 40(8):376-81. PubMed ID: 12467306
[TBL] [Abstract][Full Text] [Related]
2. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans.
Preiss R; Baumann F; Stefanovic D; Niemeyer U; Pönisch W; Niederwieser D
Cancer Chemother Pharmacol; 2004 Jun; 53(6):496-502. PubMed ID: 15138712
[TBL] [Abstract][Full Text] [Related]
3. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J; Küpker F; Blaschke G; Jürgens H
Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Wagner T; Bechrakis NE; Willerding G; Coupland SE; Fischer L; Thiel E; Korfel A
Ann Oncol; 2005 Dec; 16(12):1974-8. PubMed ID: 16219622
[TBL] [Abstract][Full Text] [Related]
5. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites.
Hempel G; Krümpelmann S; May-Manke A; Hohenlöchter B; Blaschke G; Jürgens H; Boos J
Cancer Chemother Pharmacol; 1997; 40(1):45-50. PubMed ID: 9137528
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Thiel E; Bechrakis NE; Willerding G; Kraemer DF; Fischer L; Korfel A
J Neurooncol; 2009 Jun; 93(2):213-7. PubMed ID: 19099202
[TBL] [Abstract][Full Text] [Related]
11. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1993; 33(1):36-42. PubMed ID: 8269587
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
[TBL] [Abstract][Full Text] [Related]
14. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
15. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
Kerbusch T; Mathĵt RA; Keizer HJ; Ouwerkerk J; Rodenhuis S; Schellens JH; Beijnen JH
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):467-77. PubMed ID: 11699611
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.
Granvil CP; Ducharme J; Leyland-Jones B; Trudeau M; Wainer IW
Cancer Chemother Pharmacol; 1996; 37(5):451-6. PubMed ID: 8599868
[TBL] [Abstract][Full Text] [Related]
18. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma.
Afsharian P; Möllgård L; Hassan Z; Xie H; Kimby E; Hassan M
Eur J Haematol; 2005 Sep; 75(3):206-11. PubMed ID: 16104876
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients.
Williams ML; Wainer IW; Granvil CP; Gehrcke B; Bernstein ML; Ducharme MP
Chirality; 1999; 11(4):301-8. PubMed ID: 10224657
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of ifosfamide and some metabolites in children.
Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
